About this trial
The incidence of surgical-site infection (SSI) and complications related to wound healing reaches 10-20% of gynecological cancer patients. Each complication may dramatically prolong the hospitalization period and increase the economic burden of hospital care. Appropriate wound care and tissue oxygenation are of special importance for wound healing. Assuming adequate perfusion, the easiest, safest, and most effective way to improve tissue oxygenation is to increase the fraction of inspired oxygen. However, there is considerable controversy as to whether supplemental oxygen actually reduces SSI and healing-related complications as to date, there is absence of relevant data.
Eligibility criteria
Qualifiers
Obese (BMI>30kg/m2) gynecological cancer patients
Optimized preoperative CBC values (hemoglobin >11g/dl, WBC 4.000-11.000 X 109/L, platelets 150,000 to 400,000 X 109/L)
In the case of neoadjuvant therapy an interval longer than three weeks between the last cycle and the operation
Disqualifiers
Active immunosuppresion
Preexisting infection of the abdominal wall
Preexisting sepsis
Trial design
Treatments tested in this trial
- Supplemental oxygen therapy